| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | high-affinity L-glutamate transmembrane transporter activity | 1.10e-04 | 5 | 67 | 2 | GO:0005314 | |
| GeneOntologyMolecularFunction | glutamate:sodium symporter activity | 1.10e-04 | 5 | 67 | 2 | GO:0015501 | |
| GeneOntologyBiologicalProcess | positive regulation of protein oxidation | 1.04e-05 | 2 | 67 | 2 | GO:1904808 | |
| GeneOntologyBiologicalProcess | regulation of protein oxidation | 1.04e-05 | 2 | 67 | 2 | GO:1904806 | |
| GeneOntologyBiologicalProcess | focal adhesion assembly | 1.59e-05 | 97 | 67 | 5 | GO:0048041 | |
| GeneOntologyBiologicalProcess | negative regulation of cell-substrate junction organization | 2.16e-05 | 17 | 67 | 3 | GO:0150118 | |
| GeneOntologyBiologicalProcess | negative regulation of focal adhesion assembly | 2.16e-05 | 17 | 67 | 3 | GO:0051895 | |
| GeneOntologyBiologicalProcess | cell-substrate junction assembly | 2.67e-05 | 108 | 67 | 5 | GO:0007044 | |
| GeneOntologyBiologicalProcess | cell-substrate junction organization | 3.62e-05 | 115 | 67 | 5 | GO:0150115 | |
| GeneOntologyBiologicalProcess | regulation of focal adhesion assembly | 7.93e-05 | 70 | 67 | 4 | GO:0051893 | |
| GeneOntologyBiologicalProcess | regulation of cell-substrate junction assembly | 7.93e-05 | 70 | 67 | 4 | GO:0090109 | |
| GeneOntologyBiologicalProcess | regulation of cell-substrate junction organization | 1.04e-04 | 75 | 67 | 4 | GO:0150116 | |
| GeneOntologyBiologicalProcess | response to nitrogen compound | SCN11A THBS1 FAT1 INHBB PKLR LRP1 AHSG ITGA2 SLC1A3 SMAD3 IFNA16 SOS1 SOS2 | 1.96e-04 | 1272 | 67 | 13 | GO:1901698 |
| GeneOntologyBiologicalProcess | response to monosaccharide | 2.53e-04 | 272 | 67 | 6 | GO:0034284 | |
| GeneOntologyBiologicalProcess | regulation of pro-B cell differentiation | 2.87e-04 | 8 | 67 | 2 | GO:2000973 | |
| GeneOntologyBiologicalProcess | negative regulation of cell junction assembly | 3.20e-04 | 41 | 67 | 3 | GO:1901889 | |
| Domain | TraB | 3.91e-05 | 3 | 68 | 2 | PF01963 | |
| Domain | Pheromone_shutdown_TraB | 3.91e-05 | 3 | 68 | 2 | IPR002816 | |
| Domain | Na-dicarboxylate_symporter | 2.71e-04 | 7 | 68 | 2 | IPR001991 | |
| Domain | NA_DICARBOXYL_SYMP_1 | 2.71e-04 | 7 | 68 | 2 | PS00713 | |
| Domain | NA_DICARBOXYL_SYMP_2 | 2.71e-04 | 7 | 68 | 2 | PS00714 | |
| Domain | Na-dicarboxylate_symporter_CS | 2.71e-04 | 7 | 68 | 2 | IPR018107 | |
| Domain | SDF | 2.71e-04 | 7 | 68 | 2 | PF00375 | |
| Domain | - | 2.71e-04 | 7 | 68 | 2 | 1.10.3860.10 | |
| Domain | DHC_N1 | 3.61e-04 | 8 | 68 | 2 | PF08385 | |
| Domain | Dynein_heavy_dom-1 | 3.61e-04 | 8 | 68 | 2 | IPR013594 | |
| Domain | Na_channel_asu | 5.77e-04 | 10 | 68 | 2 | IPR001696 | |
| Domain | Na_trans_assoc | 5.77e-04 | 10 | 68 | 2 | IPR010526 | |
| Domain | Na_trans_assoc | 5.77e-04 | 10 | 68 | 2 | PF06512 | |
| Domain | Dynein_heavy_chain_D4_dom | 1.16e-03 | 14 | 68 | 2 | IPR024317 | |
| Domain | Dynein_HC_stalk | 1.16e-03 | 14 | 68 | 2 | IPR024743 | |
| Domain | Dynein_heavy_dom-2 | 1.16e-03 | 14 | 68 | 2 | IPR013602 | |
| Domain | DHC_N2 | 1.16e-03 | 14 | 68 | 2 | PF08393 | |
| Domain | MT | 1.16e-03 | 14 | 68 | 2 | PF12777 | |
| Domain | AAA_8 | 1.16e-03 | 14 | 68 | 2 | PF12780 | |
| Domain | ATPase_dyneun-rel_AAA | 1.16e-03 | 14 | 68 | 2 | IPR011704 | |
| Domain | Ras_G-nucl-exch_fac_CS | 1.16e-03 | 14 | 68 | 2 | IPR019804 | |
| Domain | AAA_5 | 1.16e-03 | 14 | 68 | 2 | PF07728 | |
| Domain | Channel_four-helix_dom | 1.17e-03 | 57 | 68 | 3 | IPR027359 | |
| Domain | - | 1.17e-03 | 57 | 68 | 3 | 1.20.120.350 | |
| Domain | DHC_fam | 1.33e-03 | 15 | 68 | 2 | IPR026983 | |
| Domain | Dynein_heavy_dom | 1.33e-03 | 15 | 68 | 2 | IPR004273 | |
| Domain | Dynein_heavy | 1.33e-03 | 15 | 68 | 2 | PF03028 | |
| Domain | DH_1 | 1.57e-03 | 63 | 68 | 3 | PS00741 | |
| Domain | AAA+_ATPase | 1.88e-03 | 144 | 68 | 4 | IPR003593 | |
| Domain | AAA | 1.88e-03 | 144 | 68 | 4 | SM00382 | |
| Domain | RhoGEF | 1.95e-03 | 68 | 68 | 3 | SM00325 | |
| Domain | RhoGEF | 2.12e-03 | 70 | 68 | 3 | PF00621 | |
| Domain | DH_2 | 2.12e-03 | 70 | 68 | 3 | PS50010 | |
| Domain | DH-domain | 2.21e-03 | 71 | 68 | 3 | IPR000219 | |
| Domain | - | 2.21e-03 | 71 | 68 | 3 | 1.20.900.10 | |
| Domain | RasGEFN | 2.38e-03 | 20 | 68 | 2 | SM00229 | |
| Domain | RasGEF_N | 2.62e-03 | 21 | 68 | 2 | PF00618 | |
| Domain | Ras-like_Gua-exchang_fac_N | 2.88e-03 | 22 | 68 | 2 | IPR000651 | |
| Domain | RASGEF_NTER | 2.88e-03 | 22 | 68 | 2 | PS50212 | |
| Domain | Ephrin_rec_like | 3.71e-03 | 25 | 68 | 2 | SM01411 | |
| Domain | Tyr-kin_ephrin_A/B_rcpt-like | 3.71e-03 | 25 | 68 | 2 | IPR011641 | |
| Domain | EGF_CA | 3.81e-03 | 86 | 68 | 3 | PF07645 | |
| Domain | RASGEF | 4.01e-03 | 26 | 68 | 2 | PS00720 | |
| Domain | RASGEF_CAT | 4.98e-03 | 29 | 68 | 2 | PS50009 | |
| Domain | RasGEF | 5.32e-03 | 30 | 68 | 2 | PF00617 | |
| Domain | - | 5.32e-03 | 30 | 68 | 2 | 1.10.840.10 | |
| Domain | Ras_GEF_dom | 5.32e-03 | 30 | 68 | 2 | IPR023578 | |
| Domain | RASGEF_cat_dom | 5.32e-03 | 30 | 68 | 2 | IPR001895 | |
| Domain | RasGEF | 5.32e-03 | 30 | 68 | 2 | SM00147 | |
| Pathway | REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS | 1.66e-04 | 31 | 49 | 3 | M877 | |
| Pathway | KEGG_MEDICUS_REFERENCE_REGULATION_OF_GF_RTK_RAS_ERK_SIGNALING_PATHWAY_ADAPTOR_PROTEINS | 5.23e-04 | 10 | 49 | 2 | M47930 | |
| Pathway | WP_ENVELOPE_PROTEINS_AND_THEIR_POTENTIAL_ROLES_IN_EDMD_PHYSIOPATHOLOGY | 5.39e-04 | 46 | 49 | 3 | M39828 | |
| Pathway | KEGG_FOCAL_ADHESION | 6.14e-04 | 199 | 49 | 5 | M7253 | |
| Pathway | REACTOME_INTERLEUKIN_15_SIGNALING | 6.38e-04 | 11 | 49 | 2 | MM15578 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_RALGDS_SIGNALING_PATHWAY | 6.38e-04 | 11 | 49 | 2 | M47436 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_RASSF1_SIGNALING_PATHWAY | 6.38e-04 | 11 | 49 | 2 | M47432 | |
| Pathway | REACTOME_NERVOUS_SYSTEM_DEVELOPMENT | 7.50e-04 | 575 | 49 | 8 | M29853 | |
| Pathway | REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK | 7.74e-04 | 52 | 49 | 3 | MM14743 | |
| Pathway | REACTOME_L1CAM_INTERACTIONS | 8.12e-04 | 121 | 49 | 4 | M872 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_JNK_SIGNALING_PATHWAY | 9.01e-04 | 13 | 49 | 2 | M47594 | |
| Pathway | REACTOME_ACTIVATION_OF_RAC1 | 9.01e-04 | 13 | 49 | 2 | M6322 | |
| Pathway | KEGG_MEDICUS_VARIANT_BCR_ABL_FUSION_KINASE_TO_RAS_ERK_SIGNALING_PATHWAY | 1.05e-03 | 14 | 49 | 2 | M47364 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_KIT_TO_RAS_ERK_SIGNALING_PATHWAY | 1.05e-03 | 14 | 49 | 2 | M47365 | |
| Pathway | KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_RAS_ERK_SIGNALING_PATHWAY | 1.05e-03 | 14 | 49 | 2 | M47366 | |
| Pathway | KEGG_MEDICUS_VARIANT_DUPLICATION_OR_MUTATION_ACTIVATED_FLT3_TO_RAS_PI3K_SIGNALING_PATHWAY | 1.05e-03 | 14 | 49 | 2 | M47390 | |
| Pathway | KEGG_MEDICUS_VARIANT_AMPLIFIED_PDGFR_TO_RAS_ERK_SIGNALING_PATHWAY | 1.05e-03 | 14 | 49 | 2 | M47378 | |
| Pathway | REACTOME_INTERLEUKIN_15_SIGNALING | 1.05e-03 | 14 | 49 | 2 | M27858 | |
| Pathway | KEGG_MEDICUS_VARIANT_MET_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY | 1.05e-03 | 14 | 49 | 2 | M47488 | |
| Pathway | REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK | 1.12e-03 | 59 | 49 | 3 | M11215 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_MET_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47367 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_PI3K_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47389 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_EGFR_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47375 | |
| Pathway | KEGG_MEDICUS_VARIANT_AMPLIFIED_FGFR_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47380 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_PYK2_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47592 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HBV_HBX_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47593 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_INACTIVATED_FGF17_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47640 | |
| Pathway | KEGG_MEDICUS_VARIANT_IGF2_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47485 | |
| Pathway | KEGG_MEDICUS_REFERENCE_HGF_MET_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47473 | |
| Pathway | KEGG_MEDICUS_REFERENCE_FLT3LG_FLT3_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47474 | |
| Pathway | KEGG_MEDICUS_REFERENCE_FLT3LG_FLT3_RAS_PI3K_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47475 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TGFA_EGFR_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47480 | |
| Pathway | KEGG_MEDICUS_VARIANT_EGF_OVEREXPRESSION_TO_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47495 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EREG_EGFR_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47496 | |
| Pathway | KEGG_MEDICUS_REFERENCE_AREG_EGFR_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47497 | |
| Pathway | KEGG_MEDICUS_REFERENCE_KITLG_KIT_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47472 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HCMV_GB_TO_PDGFR_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47535 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E5_TO_EGFR_RAS_ERK_SIGNALING_PATHWAY | 1.21e-03 | 15 | 49 | 2 | M47531 | |
| Pathway | REACTOME_SIGNALING_BY_ACTIVIN | 1.21e-03 | 15 | 49 | 2 | MM14593 | |
| Pathway | REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH | 1.35e-03 | 63 | 49 | 3 | M11187 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_EGFR_RAS_ERK_SIGNALING_PATHWAY | 1.38e-03 | 16 | 49 | 2 | M47363 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_ACTIVATED_FGFR3_TO_RAS_ERK_SIGNALING_PATHWAY | 1.38e-03 | 16 | 49 | 2 | M47373 | |
| Pathway | KEGG_MEDICUS_REFERENCE_EGF_ERBB2_RAS_ERK_SIGNALING_PATHWAY | 1.38e-03 | 16 | 49 | 2 | M47381 | |
| Pathway | KEGG_MEDICUS_REFERENCE_P4_PR_RAS_ERK_SIGNALING_PATHWAY | 1.38e-03 | 16 | 49 | 2 | M47804 | |
| Pathway | WP_MAPK_PATHWAY_IN_CONGENITAL_THYROID_CANCER | 1.38e-03 | 16 | 49 | 2 | M39882 | |
| Pathway | KEGG_MEDICUS_REFERENCE_IGF_IGF1R_RAS_ERK_SIGNALING_PATHWAY | 1.38e-03 | 16 | 49 | 2 | M47483 | |
| Pathway | WP_IRON_METABOLISM_DISORDERS | 1.56e-03 | 17 | 49 | 2 | M48053 | |
| Pathway | KEGG_MEDICUS_REFERENCE_PDGF_PDGFR_RAS_ERK_SIGNALING_PATHWAY | 1.56e-03 | 17 | 49 | 2 | M47376 | |
| Pathway | REACTOME_SIGNALING_BY_ACTIVIN | 1.56e-03 | 17 | 49 | 2 | M26965 | |
| Pathway | REACTOME_RHOB_GTPASE_CYCLE | 1.76e-03 | 69 | 49 | 3 | MM15596 | |
| Pathway | REACTOME_RHOB_GTPASE_CYCLE | 1.83e-03 | 70 | 49 | 3 | M41806 | |
| Pathway | REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE | 1.83e-03 | 70 | 49 | 3 | MM14824 | |
| Pathway | REACTOME_RHOC_GTPASE_CYCLE | 1.83e-03 | 70 | 49 | 3 | MM15597 | |
| Pathway | WP_HEPATITIS_B_INFECTION | 1.84e-03 | 151 | 49 | 4 | M39801 | |
| Pathway | KEGG_CHRONIC_MYELOID_LEUKEMIA | 2.07e-03 | 73 | 49 | 3 | M321 | |
| Pathway | REACTOME_RHOC_GTPASE_CYCLE | 2.15e-03 | 74 | 49 | 3 | M41807 | |
| Pathway | REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE | 2.32e-03 | 76 | 49 | 3 | M19832 | |
| Pathway | REACTOME_G_ALPHA_12_13_SIGNALLING_EVENTS | 2.41e-03 | 77 | 49 | 3 | MM15044 | |
| Pathway | REACTOME_G_ALPHA_12_13_SIGNALLING_EVENTS | 2.69e-03 | 80 | 49 | 3 | M800 | |
| Pubmed | 5.95e-07 | 9 | 68 | 3 | 14679214 | ||
| Pubmed | Mutation of ARHGAP9 in patients with coronary spastic angina. | 9.38e-07 | 38 | 68 | 4 | 19911011 | |
| Pubmed | 3.33e-06 | 323 | 68 | 7 | 24797263 | ||
| Pubmed | Expression and evolution of the Tiki1 and Tiki2 genes in vertebrates. | 3.77e-06 | 2 | 68 | 2 | 25354456 | |
| Pubmed | A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17. | 3.77e-06 | 2 | 68 | 2 | 8307589 | |
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 14991768 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 25393517 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 25973715 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 11144347 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 1631150 | ||
| Pubmed | SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology. | 3.77e-06 | 2 | 68 | 2 | 34205562 | |
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 9045712 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 9372945 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 17154366 | ||
| Pubmed | Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia. | 3.77e-06 | 2 | 68 | 2 | 36010887 | |
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 8275713 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 27995606 | ||
| Pubmed | 3.77e-06 | 2 | 68 | 2 | 24877199 | ||
| Pubmed | Mapping of five subtype genes for muscarinic acetylcholine receptor to mouse chromosomes. | 4.77e-06 | 17 | 68 | 3 | 10549128 | |
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 20696764 | ||
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 8250913 | ||
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 22674573 | ||
| Pubmed | Functional redundancy of Sos1 and Sos2 for lymphopoiesis and organismal homeostasis and survival. | 1.13e-05 | 3 | 68 | 2 | 24043312 | |
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 12628188 | ||
| Pubmed | Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. | 1.13e-05 | 3 | 68 | 2 | 18653767 | |
| Pubmed | Differential Role of the RasGEFs Sos1 and Sos2 in Mouse Skin Homeostasis and Carcinogenesis. | 1.13e-05 | 3 | 68 | 2 | 29844066 | |
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 21252237 | ||
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 25557874 | ||
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 33519378 | ||
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 22586275 | ||
| Pubmed | Disassembly of Son-of-sevenless proteins from Grb2 during p21ras desensitization by insulin. | 1.13e-05 | 3 | 68 | 2 | 7829473 | |
| Pubmed | 1.13e-05 | 3 | 68 | 2 | 7629138 | ||
| Pubmed | Deciphering the complex role of thrombospondin-1 in glioblastoma development. | 1.13e-05 | 3 | 68 | 2 | 30850588 | |
| Pubmed | Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. | 1.59e-05 | 25 | 68 | 3 | 8493579 | |
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 12270917 | ||
| Pubmed | Tiki1 is required for head formation via Wnt cleavage-oxidation and inactivation. | 2.25e-05 | 4 | 68 | 2 | 22726442 | |
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 16600856 | ||
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 26147384 | ||
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 10397731 | ||
| Pubmed | A new member of the amphiphysin family connecting endocytosis and signal transduction pathways. | 2.25e-05 | 4 | 68 | 2 | 9182529 | |
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 7775583 | ||
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 31337738 | ||
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 34731499 | ||
| Pubmed | 2.25e-05 | 4 | 68 | 2 | 10940929 | ||
| Pubmed | 3.57e-05 | 94 | 68 | 4 | 32062451 | ||
| Pubmed | 3.75e-05 | 5 | 68 | 2 | 9030684 | ||
| Pubmed | 3.75e-05 | 5 | 68 | 2 | 18826955 | ||
| Pubmed | A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis. | 3.75e-05 | 5 | 68 | 2 | 36213818 | |
| Pubmed | 3.75e-05 | 5 | 68 | 2 | 23209318 | ||
| Pubmed | USP15 is a deubiquitylating enzyme for receptor-activated SMADs. | 3.75e-05 | 5 | 68 | 2 | 21947082 | |
| Pubmed | 5.06e-05 | 335 | 68 | 6 | 15741177 | ||
| Pubmed | 5.62e-05 | 6 | 68 | 2 | 10675333 | ||
| Pubmed | 5.62e-05 | 6 | 68 | 2 | 31023188 | ||
| Pubmed | 5.62e-05 | 6 | 68 | 2 | 14764585 | ||
| Pubmed | Activation of Rac GTPase by p75 is necessary for c-jun N-terminal kinase-mediated apoptosis. | 5.74e-05 | 38 | 68 | 3 | 11756498 | |
| Pubmed | 6.40e-05 | 214 | 68 | 5 | 22199357 | ||
| Pubmed | The rasGAP-binding protein, Dok-1, mediates activin signaling via serine/threonine kinase receptors. | 7.86e-05 | 7 | 68 | 2 | 11927552 | |
| Pubmed | 7.86e-05 | 7 | 68 | 2 | 15173068 | ||
| Pubmed | 7.86e-05 | 7 | 68 | 2 | 30720883 | ||
| Pubmed | 7.86e-05 | 7 | 68 | 2 | 8276400 | ||
| Pubmed | Erythropoietin receptor Y479 couples to ERK1/2 activation via recruitment of phospholipase Cgamma. | 7.86e-05 | 7 | 68 | 2 | 15953601 | |
| Pubmed | 8.34e-05 | 43 | 68 | 3 | 12376548 | ||
| Pubmed | 8.94e-05 | 44 | 68 | 3 | 31273033 | ||
| Pubmed | 1.05e-04 | 8 | 68 | 2 | 23452850 | ||
| Pubmed | Germline gain-of-function mutations in SOS1 cause Noonan syndrome. | 1.05e-04 | 8 | 68 | 2 | 17143285 | |
| Pubmed | USP4 Auto-Deubiquitylation Promotes Homologous Recombination. | 1.05e-04 | 8 | 68 | 2 | 26455393 | |
| Pubmed | 1.05e-04 | 8 | 68 | 2 | 22344298 | ||
| Pubmed | ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1. | 1.09e-04 | 1201 | 68 | 10 | 35696571 | |
| Pubmed | 1.34e-04 | 9 | 68 | 2 | 19289468 | ||
| Pubmed | 1.34e-04 | 9 | 68 | 2 | 8943292 | ||
| Pubmed | 1.48e-04 | 52 | 68 | 3 | 26590417 | ||
| Pubmed | 1.51e-04 | 257 | 68 | 5 | 16335952 | ||
| Pubmed | USP9X-mediated NRP1 deubiquitination promotes liver fibrosis by activating hepatic stellate cells. | 1.68e-04 | 10 | 68 | 2 | 36653359 | |
| Pubmed | Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy. | 1.74e-04 | 55 | 68 | 3 | 38945485 | |
| Pubmed | Thbs1 regulates skeletal muscle mass in a TGFβ-Smad2/3-ATF4-dependent manner. | 2.05e-04 | 11 | 68 | 2 | 38678560 | |
| Pubmed | 2.05e-04 | 11 | 68 | 2 | 7720577 | ||
| Pubmed | Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. | 2.17e-04 | 1061 | 68 | 9 | 33845483 | |
| Pubmed | Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). | 2.26e-04 | 60 | 68 | 3 | 12787561 | |
| Pubmed | 2.45e-04 | 12 | 68 | 2 | 15728722 | ||
| Pubmed | 2.45e-04 | 12 | 68 | 2 | 22031545 | ||
| Pubmed | 2.90e-04 | 13 | 68 | 2 | 17884984 | ||
| Pubmed | Phosphatidylinositol 4-kinase IIα function at endosomes is regulated by the ubiquitin ligase Itch. | 2.90e-04 | 13 | 68 | 2 | 23146885 | |
| Pubmed | 3.07e-04 | 467 | 68 | 6 | 30194290 | ||
| Pubmed | 3.38e-04 | 14 | 68 | 2 | 9373155 | ||
| Pubmed | 3.38e-04 | 14 | 68 | 2 | 7590978 | ||
| Pubmed | 3.38e-04 | 14 | 68 | 2 | 15277382 | ||
| Pubmed | The ubiquitin ligase Ubr4 controls stability of podocin/MEC-2 supercomplexes. | 3.41e-04 | 69 | 68 | 3 | 26792178 | |
| Pubmed | 3.71e-04 | 71 | 68 | 3 | 33541421 | ||
| Pubmed | 3.89e-04 | 15 | 68 | 2 | 20301303 | ||
| Pubmed | A genome-wide association study on obesity and obesity-related traits. | 3.89e-04 | 15 | 68 | 2 | 21552555 | |
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | 4.31e-04 | 1425 | 68 | 10 | 30948266 | |
| Pubmed | 4.44e-04 | 16 | 68 | 2 | 38750011 | ||
| Pubmed | 4.44e-04 | 16 | 68 | 2 | 21939397 | ||
| Pubmed | 4.70e-04 | 329 | 68 | 5 | 17474147 | ||
| Pubmed | NudCL2 regulates cell migration by stabilizing both myosin-9 and LIS1 with Hsp90. | 4.97e-04 | 333 | 68 | 5 | 32665550 | |
| Pubmed | A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation. | 5.31e-04 | 724 | 68 | 7 | 36232890 | |
| Pubmed | 5.46e-04 | 340 | 68 | 5 | 24332808 | ||
| Pubmed | The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. | 5.47e-04 | 81 | 68 | 3 | 20697350 | |
| Pubmed | 5.65e-04 | 18 | 68 | 2 | 19531499 | ||
| Pubmed | 5.65e-04 | 18 | 68 | 2 | 22566683 | ||
| GeneFamily | Pleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing | 5.17e-04 | 66 | 43 | 3 | 722 | |
| ToppCell | pdx-Tumor_cells-T0|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 3.95e-07 | 185 | 68 | 6 | 1d874608aa2062024323512f68889219471b2f00 | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-myeloid-myeloid_monocytic|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.54e-07 | 196 | 68 | 6 | 89ff93cbfbe39fbdf2498e8fdc5d61a0ecb26fc9 | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-myeloid-myeloid_monocytic-monocyte|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.54e-07 | 196 | 68 | 6 | 09574bfeb1d3da53b5471cfb0602946d328b3b5c | |
| ToppCell | myeloid-Monocyte|myeloid / Lineage, cell class and subclass | 5.70e-07 | 197 | 68 | 6 | 6acf059cee6ba6bdeacc089b090d72336790972a | |
| ToppCell | COVID-19_Mild|World / Disease condition and Cell class | 5.87e-07 | 198 | 68 | 6 | 61ceb2245b6cb58e308b999a61d218c89dbc615e | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 6.23e-07 | 200 | 68 | 6 | dccec522ab0d7fff62ad6273b02aa9022dbbb8eb | |
| ToppCell | mild-Myeloid-CD14_Monocytes_3|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 5.40e-06 | 165 | 68 | 5 | a6547bb2c9c40b4878325da19b9def0ef644fa25 | |
| ToppCell | droplet-Spleen-SPLEEN-30m-Myeloid-macrophage|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.81e-06 | 178 | 68 | 5 | 6c1b5087581ca8cea976d89ea6f34088c8fc3668 | |
| ToppCell | E18.5-samps-Mesenchymal-Matrix_fibroblast|E18.5-samps / Age Group, Lineage, Cell class and subclass | 8.69e-06 | 182 | 68 | 5 | ceb37c214662a48efb56ab0d015977c6fab478b0 | |
| ToppCell | 5'-Adult-Appendix-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 9.66e-06 | 186 | 68 | 5 | 7582b5154d8e5a4434817b5ab77a10b789ea2288 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D175|Adult / Lineage, Cell type, age group and donor | 9.91e-06 | 187 | 68 | 5 | e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f | |
| ToppCell | Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.07e-05 | 190 | 68 | 5 | 18c020ca9a23399214133ec255ab870e0060f2e1 | |
| ToppCell | Control-Stromal_mesenchymal|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.10e-05 | 191 | 68 | 5 | 14057205ddb9b4bbc582d1358d13cf36d979a61b | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal-mesenchymal_stem_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.13e-05 | 192 | 68 | 5 | 11088878043a6ff95ba1970361256a82e434b80a | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.15e-05 | 193 | 68 | 5 | 1db487e5f81849740d57cc3e2b5739e8f7581efb | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar-Macro_c6-VCAN|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.15e-05 | 193 | 68 | 5 | 52f5b0fbb8ca706206c65e7edbb1ddbd380aebae | |
| ToppCell | Adult-Immune-interstitial_macrophage_(C1Q_positive)|Adult / Lineage, Cell type, age group and donor | 1.15e-05 | 193 | 68 | 5 | 31c0978ba78c9516d498aec0798902e57555e557 | |
| ToppCell | LV-14._Fibroblast_III|LV / Chamber and Cluster_Paper | 1.18e-05 | 194 | 68 | 5 | 927c26aea0147f7a4b8fb3f192de4de263f1b978 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 1.18e-05 | 194 | 68 | 5 | 8c37bedb23285735ff3828db3889897fada8c95d | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.18e-05 | 194 | 68 | 5 | a94f9f7179a5733e3c378ff8b337e288785433a1 | |
| ToppCell | RA-08._Macrophage|RA / Chamber and Cluster_Paper | 1.18e-05 | 194 | 68 | 5 | ac26e5c71d5069622de72fa25a9c920887ac2c19 | |
| ToppCell | droplet-Limb_Muscle-nan-21m-Mesenchymal-chondrocyte-like|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.21e-05 | 195 | 68 | 5 | d2c9c58b46bf96f9a536e177b995e340b55c6750 | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_macrophage|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.21e-05 | 195 | 68 | 5 | 4e9513a7ea69fa9fc8e9ff2da8ef3f44e8fdc70d | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_macrophage-macrophage|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.21e-05 | 195 | 68 | 5 | a25a342380e258b784227f7298f609ccaa1f9ce7 | |
| ToppCell | facs-Thymus-Thymus_Epithelium|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.24e-05 | 196 | 68 | 5 | 6bc1187dfc4860a4e09032d7ea87ba3d9fe9f363 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.24e-05 | 196 | 68 | 5 | c8c89e469402e11aa2a9561e859b6fd1fb66c39b | |
| ToppCell | COVID-19_Moderate-Non-classical_Monocyte|COVID-19_Moderate / disease group, cell group and cell class | 1.24e-05 | 196 | 68 | 5 | 256c557fa11414c9d2cbb1fcff33f482ee1c78ac | |
| ToppCell | (7)_Monocyte|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 1.24e-05 | 196 | 68 | 5 | 0232167559dcd2d86ee8b78017cf5f2a084b2cb7 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 1.24e-05 | 196 | 68 | 5 | 1450cb69c5bf469e97c03bf1890f6f7c54165b8a | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_adipo|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.27e-05 | 197 | 68 | 5 | 5afddde4e2b5cd55abe11e9b9efae02dbdc3da3a | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_adipo-stroma-adipo-CAR|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.27e-05 | 197 | 68 | 5 | 1baffd087ca194a7355fefbb3bf67befb14fe2de | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_adipo-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.27e-05 | 197 | 68 | 5 | b9745e382baa2725dfcae060701fb53f6c8a31fa | |
| ToppCell | COVID-19-lung-Fibroblast|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.31e-05 | 198 | 68 | 5 | 3ec01a55ade5e1627258cc3cfebb2c3207a4cb43 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 1.31e-05 | 198 | 68 | 5 | 17dc055e2a289496d9c5cdbf3297bdf906dc6d22 | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Monocytic-Classical_monocytes|lymph-node_spleen / Manually curated celltypes from each tissue | 1.31e-05 | 198 | 68 | 5 | 187a04d498f0b355cb11c81172721698818082d6 | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Monocytic|lymph-node_spleen / Manually curated celltypes from each tissue | 1.31e-05 | 198 | 68 | 5 | 065c8a9655d19f93dfdb453c78bbfe7d857caf3e | |
| ToppCell | mLN-(4)_Monocyte|mLN / shred on region, Cell_type, and subtype | 1.34e-05 | 199 | 68 | 5 | 6795ff31f92580195c9db776951f99d647484d24 | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_monocytic|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.34e-05 | 199 | 68 | 5 | 7dde5c02fcae64cd2d68f607500f2a46b97851fd | |
| ToppCell | mLN-Monocyte|mLN / Region, Cell class and subclass | 1.34e-05 | 199 | 68 | 5 | 241f790cd5d8a9b2451333deecc826a673bae70a | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.34e-05 | 199 | 68 | 5 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-myeloid|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.34e-05 | 199 | 68 | 5 | 0f3ce61bbae69f7e333ed8dacf7257645624e163 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte-Mono_c2-CD14-HLA-DPB1|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.34e-05 | 199 | 68 | 5 | 97af159fa3a5533ec3d45331fb80c6da8a715aa5 | |
| ToppCell | mLN-Monocyte-Monocyte|mLN / Region, Cell class and subclass | 1.34e-05 | 199 | 68 | 5 | dcee372774c169a3048bdaed3734b3215bf8ffad | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.34e-05 | 199 | 68 | 5 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_monocytic-monocyte|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.34e-05 | 199 | 68 | 5 | 84879280851380e5bfe6bd48b6bbf57aedf6e003 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.34e-05 | 199 | 68 | 5 | 667b8b47a5b388506e3177b46747267fad8024f6 | |
| ToppCell | mLN-(4)_Monocyte-(40)_Monocyte|mLN / shred on region, Cell_type, and subtype | 1.34e-05 | 199 | 68 | 5 | bcbb1eee8d79bf670dbe113094c3a292b135ce2f | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.37e-05 | 200 | 68 | 5 | 72ea9882a8ed26fa1534aeb6ba0d1897dccc20c5 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.37e-05 | 200 | 68 | 5 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW19-Macroglial|GW19 / Sample Type, Dataset, Time_group, and Cell type. | 1.37e-05 | 200 | 68 | 5 | 3a954d9d542e52c9b181f0850a09b1bff0a0c82d | |
| ToppCell | LPS_only-Endothelial-Endothelial-Activated_Alv_Cap|LPS_only / Treatment groups by lineage, cell group, cell type | 1.37e-05 | 200 | 68 | 5 | edb64556b3fefe3144f73b6efe23b9ffd34091d2 | |
| ToppCell | LPS_IL1RA-Endothelial|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.37e-05 | 200 | 68 | 5 | 5c092b2ecc081b5d04476c56333c338cd89ab984 | |
| ToppCell | mLN-Macrophage-LYVE1_Macrophage|Macrophage / Region, Cell class and subclass | 1.37e-05 | 200 | 68 | 5 | e3c15e0e1c2602b0cc9ab8cc50c978d265350c94 | |
| ToppCell | Control_saline-Endothelial-Endothelial-Gen_Cap|Control_saline / Treatment groups by lineage, cell group, cell type | 1.37e-05 | 200 | 68 | 5 | 3b97920e1e6e2f09ddba2a861baa9c00c2970f4c | |
| ToppCell | Parenchymal-10x5prime-Immune_Myeloid-Macrophage_other-Macrophage_intravascular|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.37e-05 | 200 | 68 | 5 | 77a68e8fd97a3f3467d25032067fd7ad52ab8522 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 1.37e-05 | 200 | 68 | 5 | a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.37e-05 | 200 | 68 | 5 | 34f52003988ce6329d8deeee1ab875fa77e01e9d | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.62e-05 | 142 | 68 | 4 | 5b6b0c611c83b23ef7289854a515b78f6cf84500 | |
| ToppCell | E18.5-samps-Endothelial-Mature_fetal_endothelial-endothelial_cells_B|E18.5-samps / Age Group, Lineage, Cell class and subclass | 1.13e-04 | 163 | 68 | 4 | d6f9b7280c44d120df5a72dfc2ebb26ffbb5752b | |
| ToppCell | facs-Marrow-T_cells-18m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.13e-04 | 163 | 68 | 4 | 30cd95d4f37bd54c1fde54960cb005db58bdd30c | |
| ToppCell | facs-Marrow-T_cells-18m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.13e-04 | 163 | 68 | 4 | ab934cb986495adfc8dbe5a276577f2a8fb6ee03 | |
| ToppCell | BAL-Severe-cDC_8|Severe / Compartment, Disease Groups and Clusters | 1.16e-04 | 164 | 68 | 4 | e8cbe7e01eca32886eb44e02d5333056b6bebc50 | |
| ToppCell | LV-16._Neuronal|World / Chamber and Cluster_Paper | 1.18e-04 | 165 | 68 | 4 | 6ed52cb756d21addf46c7f6c457458b01339fe04 | |
| ToppCell | Adult-Immune-interstitial_macrophage_(C1Q_positive)-D122|Adult / Lineage, Cell type, age group and donor | 1.21e-04 | 166 | 68 | 4 | be284e2e596390f05305c7bcfc316f87b963fc0b | |
| ToppCell | (2)_MNPs-(2)_Mono_macro|(2)_MNPs / Oesophagus cell shreds on cell class (v1) and cell subclass (v1) | 1.29e-04 | 64 | 68 | 3 | 494f500ccceeedf45b4ded919b237a7fb75827c4 | |
| ToppCell | LV-16._Neuronal|LV / Chamber and Cluster_Paper | 1.30e-04 | 169 | 68 | 4 | a8fc8ab0f0757e939e213efb61c03cfe390bf7d2 | |
| ToppCell | droplet-Spleen-SPLEEN-1m-Hematologic|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.33e-04 | 170 | 68 | 4 | 7cb7ad9ab064b6ea452545d145e5b1d4090cd4c1 | |
| ToppCell | droplet-Spleen-SPLEEN-1m-Hematologic-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.33e-04 | 170 | 68 | 4 | db7cee7e518debb2cbe9eeae05d47e14b69cb8e3 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.6.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.39e-04 | 172 | 68 | 4 | c8ea80042faf923b08ff03d73100533d521d73ef | |
| ToppCell | droplet-Marrow-BM-1m-Lymphocytic-plasma_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.55e-04 | 177 | 68 | 4 | 26bad614560609d318bfc9c235a698bca4e1c22c | |
| ToppCell | droplet-Spleen-nan-24m-Hematologic-proerythroblast|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.55e-04 | 177 | 68 | 4 | 5f20a1a875d6f85ec07b097e6afdb07c2f8f88ff | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.0.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.55e-04 | 177 | 68 | 4 | 68f1139fc378f351e3b9e9f392aacb150025bf03 | |
| ToppCell | droplet-Spleen-SPLEEN-30m-Hematologic-proerythroblast|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.58e-04 | 178 | 68 | 4 | be8af4d85b8835a85a168639c37857dcaa6b00bf | |
| ToppCell | wk_15-18-Mesenchymal-Chondrocyte-ASPN+_chondrocyte|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.58e-04 | 178 | 68 | 4 | a55130670aa95a87b833dd3cd2de461d779e4c06 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.62e-04 | 179 | 68 | 4 | 666072c0e8448dbaec1683d18368ec2502453f90 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.65e-04 | 180 | 68 | 4 | 08ae0f5d95c45feba68ad99788f7af7ff4c979af | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.65e-04 | 180 | 68 | 4 | bf8d13d4db1af55b8c9fe16aaccf8743e000e005 | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.65e-04 | 180 | 68 | 4 | 839defb40f7cfb2711e9025194de636533f51bcd | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Neuronal-Glial_immature-Glia_1_(DHH+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.65e-04 | 180 | 68 | 4 | b294f9db1e2ff51c94cde64fae4c2b057c0030a1 | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.65e-04 | 180 | 68 | 4 | 82965ed1b72a1873c24dd4553d39681596057316 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.65e-04 | 180 | 68 | 4 | 9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum_-18m-Epithelial-neuroepithelial_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.69e-04 | 181 | 68 | 4 | c26d3cbbc592299786d79d1b15fc6bead2aafb9a | |
| ToppCell | 10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8|Liver / Manually curated celltypes from each tissue | 1.69e-04 | 181 | 68 | 4 | f2315414e714ac86211546a935660c4be6e85f1b | |
| ToppCell | 5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.72e-04 | 182 | 68 | 4 | 3dfa9187e9d2bab1d199079d29209c4648220ada | |
| ToppCell | droplet-Heart-4Chambers-18m-Mesenchymal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.72e-04 | 182 | 68 | 4 | f4b74c2756989812abe4e7055ec8918f69d56025 | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-Myeloid-Monocytes|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.72e-04 | 182 | 68 | 4 | 1fb9bdf2e9f0a9c230f109b471672f9c31e27c82 | |
| ToppCell | E18.5-samps-Endothelial-Mature_fetal_endothelial|E18.5-samps / Age Group, Lineage, Cell class and subclass | 1.72e-04 | 182 | 68 | 4 | 7af3b2029b7f55b923d5a4b764d4292f4ea48599 | |
| ToppCell | pdx-Tumor_cells-T6|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 1.72e-04 | 182 | 68 | 4 | 7b24a4f712e1ae1525e8f1c8ec4e1fc43489cbee | |
| ToppCell | E18.5-samps-Endothelial|E18.5-samps / Age Group, Lineage, Cell class and subclass | 1.72e-04 | 182 | 68 | 4 | e2d799e6e7526176a6fe6515b8fbe4d83d3a3ea1 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.76e-04 | 183 | 68 | 4 | 7eae9b3b4d1c9b135fa7cff348393d4adec474b4 | |
| ToppCell | Fetal_29-31_weeks-Immune-enucleated_erythrocyte-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.83e-04 | 185 | 68 | 4 | e8f7da9641b6cf1db1093b4f301ce828fd3a529c | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.83e-04 | 185 | 68 | 4 | 3b2dfc8f4c87be516265dbecfc251276034d0efd | |
| ToppCell | LPS_only|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.83e-04 | 185 | 68 | 4 | a72ccb147ca505880e2da8f6a70b9d570464a691 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-airway_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.83e-04 | 185 | 68 | 4 | e58a009aaf342be019a909747b1895d5987d4daf | |
| ToppCell | droplet-Heart-4Chambers-18m-Mesenchymal-fibroblast|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.87e-04 | 186 | 68 | 4 | 35c88cc4eb388811fcac4323b549e5897fa8dc27 | |
| ToppCell | Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.87e-04 | 186 | 68 | 4 | 23b8d51d20b05795a73892d3e20e0f9b6a207820 | |
| ToppCell | 10x5'-GI_small-bowel-Myeloid_Monocytic-Nonclassical_monocytes|GI_small-bowel / Manually curated celltypes from each tissue | 1.87e-04 | 186 | 68 | 4 | a16ecf70271894a842925f232009e2623d16947e | |
| ToppCell | droplet-Heart-4Chambers-18m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.87e-04 | 186 | 68 | 4 | d998c5b00083cf2a7cd5341a98b7374b4de73c63 | |
| ToppCell | severe_influenza-RBC|World / disease group, cell group and cell class (v2) | 1.91e-04 | 187 | 68 | 4 | f846750575f318503d21ade30f5bfd2e1d4c84af | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.91e-04 | 187 | 68 | 4 | f124d2c699b717b7c02a1a70493f515b83dc2f4c | |
| Drug | Cephalosporanic acid, 7-amino [957-68-6]; Up 200; 14.6uM; HL60; HT_HG-U133A | 1.96e-06 | 199 | 67 | 7 | 1322_UP | |
| Drug | Verteporfin [129497-78-5]; Down 200; 2.8uM; MCF7; HT_HG-U133A | 6.40e-06 | 155 | 67 | 6 | 6817_DN | |
| Drug | Ethaverine hydrochloride [985-13-7]; Up 200; 9.2uM; HL60; HT_HG-U133A | 1.87e-05 | 187 | 67 | 6 | 3037_UP | |
| Drug | Betamethasone [378-44-9]; Up 200; 10.2uM; PC3; HT_HG-U133A | 2.16e-05 | 192 | 67 | 6 | 6728_UP | |
| Drug | Piperacillin sodium salt [59703-84-3]; Down 200; 7.4uM; PC3; HT_HG-U133A | 2.30e-05 | 194 | 67 | 6 | 4320_DN | |
| Drug | Orlistat; Up 200; 10uM; MCF7; HT_HG-U133A | 2.36e-05 | 195 | 67 | 6 | 6415_UP | |
| Drug | Molindone hydrochloride [15622-65-8]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 2.43e-05 | 196 | 67 | 6 | 4784_UP | |
| Drug | Bretylium tosylate [61-75-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 2.43e-05 | 196 | 67 | 6 | 5020_DN | |
| Drug | Streptomycin sulfate [3810-74-0]; Up 200; 2.8uM; MCF7; HT_HG-U133A | 2.50e-05 | 197 | 67 | 6 | 3195_UP | |
| Drug | Procainamide hydrochloride [614-39-1]; Up 200; 14.8uM; MCF7; HT_HG-U133A | 2.50e-05 | 197 | 67 | 6 | 2618_UP | |
| Drug | kryptofix 221 | 2.55e-05 | 3 | 67 | 2 | CID000123438 | |
| Drug | Oxprenolol hydrochloride [6452-73-9]; Up 200; 13.2uM; HL60; HT_HG-U133A | 2.57e-05 | 198 | 67 | 6 | 6145_UP | |
| Drug | Sulfasalazine [599-79-1]; Up 200; 10uM; MCF7; HT_HG-U133A | 2.65e-05 | 199 | 67 | 6 | 2882_UP | |
| Drug | Delsoline [509-18-2]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 2.65e-05 | 199 | 67 | 6 | 6075_DN | |
| Drug | irinotecan | 3.74e-05 | 703 | 67 | 10 | ctd:C051890 | |
| Drug | bismuth complex | 1.27e-04 | 6 | 67 | 2 | CID000457407 | |
| Drug | bromoacetone | 1.27e-04 | 6 | 67 | 2 | CID000011715 | |
| Drug | irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A | 1.49e-04 | 171 | 67 | 5 | 7535_DN | |
| Drug | silver nanoparticles | 1.54e-04 | 172 | 67 | 5 | CID000023954 | |
| Drug | 2-benzoylpyridine | 1.77e-04 | 7 | 67 | 2 | CID000007038 | |
| Drug | LY 294002; Up 200; 10uM; PC3; HT_HG-U133A | 2.21e-04 | 186 | 67 | 5 | 4463_UP | |
| Drug | n-C4H9 | 2.36e-04 | 8 | 67 | 2 | CID000137616 | |
| Drug | aspirin, USP; Down 200; 100uM; HL60; HT_HG-U133A | 2.56e-04 | 192 | 67 | 5 | 6164_DN | |
| Drug | Forskolin, from Coleus forskohlii; Down 200; 0.5uM; PC3; HT_HG-U133A | 2.56e-04 | 192 | 67 | 5 | 7104_DN | |
| Drug | Dihydroergotoxine mesylate [8067-24-1]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 2.56e-04 | 192 | 67 | 5 | 4152_DN | |
| Drug | Terbutaline hemisulfate [23031-32-5]; Down 200; 7.2uM; PC3; HT_HG-U133A | 2.62e-04 | 193 | 67 | 5 | 5764_DN | |
| Drug | Dilazep dihydrochloride [20153-98-4]; Down 200; 6uM; MCF7; HT_HG-U133A | 2.62e-04 | 193 | 67 | 5 | 2294_DN | |
| Drug | Muramic acid, N-acetyl [10597-89-4]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 2.62e-04 | 193 | 67 | 5 | 4406_DN | |
| Drug | Diflorasone Diacetate [33564-31-7]; Down 200; 8uM; HL60; HT_HG-U133A | 2.62e-04 | 193 | 67 | 5 | 2142_DN | |
| Drug | Iopamidol [60166-93-0]; Up 200; 5.2uM; MCF7; HT_HG-U133A | 2.68e-04 | 194 | 67 | 5 | 7189_UP | |
| Drug | Cefixime [79350-37-1]; Down 200; 8.8uM; HL60; HT_HG-U133A | 2.68e-04 | 194 | 67 | 5 | 1310_DN | |
| Drug | Fenofibrate [49562-28-9]; Down 200; 11uM; MCF7; HT_HG-U133A | 2.75e-04 | 195 | 67 | 5 | 7432_DN | |
| Drug | radicicol; Down 200; 0.1uM; MCF7; HG-U133A | 2.75e-04 | 195 | 67 | 5 | 489_DN | |
| Drug | Sulfamerazine [127-79-7]; Down 200; 15.2uM; MCF7; HT_HG-U133A | 2.75e-04 | 195 | 67 | 5 | 4740_DN | |
| Drug | Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 2.75e-04 | 195 | 67 | 5 | 3864_DN | |
| Drug | Cefotaxime sodium salt [64485-93-4]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 7186_UP | |
| Drug | Moricizine hydrochloride [31883-05-3]; Down 200; 8.6uM; PC3; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 7297_DN | |
| Drug | Heliotrine [303-33-3]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 4739_DN | |
| Drug | LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 5236_UP | |
| Drug | Butamben [94-25-7]; Down 200; 20.6uM; HL60; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 2531_DN | |
| Drug | Trimeprazine tartrate [4330-99-8]; Down 200; 5.4uM; HL60; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 2736_DN | |
| Drug | Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 3441_UP | |
| Drug | Nefopam hydrochloride [23327-57-3]; Up 200; 13.8uM; HL60; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 2355_UP | |
| Drug | genistein; Up 200; 10uM; HL60; HT_HG-U133A | 2.81e-04 | 196 | 67 | 5 | 6194_UP | |
| Drug | Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 6106_DN | |
| Drug | Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 5276_UP | |
| Drug | Aconitine [302-27-2]; Down 200; 6.2uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 6797_DN | |
| Drug | Cytisine (-) [485-35-8]; Down 200; 21uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 6217_DN | |
| Drug | Epirizole [18694-40-1]; Down 200; 17uM; PC3; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 1803_DN | |
| Drug | Propoxycaine hydrochloride [550-83-4]; Up 200; 12uM; HL60; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 6161_UP | |
| Drug | Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 2887_DN | |
| Drug | Cefixime [79350-37-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 3247_DN | |
| Drug | 2-propylpentanoic acid; Down 200; 50uM; PC3; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 1222_DN | |
| Drug | LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 1641_UP | |
| Drug | novobiocin sodium, USP; Down 200; 100uM; PC3; HG-U133A | 2.88e-04 | 197 | 67 | 5 | 435_DN | |
| Drug | Guanethidine sulfate [60-02-6]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 3171_DN | |
| Drug | Benserazide hydrochloride [14919-77-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 5322_DN | |
| Drug | Glutethimide, para-amino [125-84-8]; Down 200; 17.2uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 7463_DN | |
| Drug | Tranexamic acid [1197-18-8]; Up 200; 25.4uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 2248_UP | |
| Drug | Aconitine [302-27-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A | 2.88e-04 | 197 | 67 | 5 | 6797_UP | |
| Drug | Reserpinic acid hydrochloride; Down 200; 9.2uM; PC3; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 6603_DN | |
| Drug | Phenindione [83-12-5]; Down 200; 18uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 5991_DN | |
| Drug | Thyroxine (L) [51-48-9]; Down 200; 5.2uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 4150_DN | |
| Drug | Oxethazaine [126-27-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 1484_UP | |
| Drug | Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 4729_DN | |
| Drug | Clorgyline hydrochloride [17780-75-5]; Down 200; 13uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 3219_DN | |
| Drug | Betulinic acid [472-15-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 3281_DN | |
| Drug | Pargyline hydrochloride [306-07-0]; Down 200; 20.4uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 7016_DN | |
| Drug | Cimetidine [51481-61-9]; Up 200; 15.8uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 1464_UP | |
| Drug | Catechin-(+,-) hydrate [7295-85-4]; Down 200; 13.8uM; HL60; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 3012_DN | |
| Drug | Picrotoxinin [17617-45-7]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 2816_DN | |
| Drug | Methyldopate hydrochloride [2508-79-4]; Up 200; 14.6uM; PC3; HT_HG-U133A | 2.95e-04 | 198 | 67 | 5 | 6640_UP | |
| Drug | Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; MCF7; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 5006_DN | |
| Drug | Propranolol hydrochloride [318-98-9]; Up 200; 13.6uM; MCF7; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 5358_UP | |
| Drug | Nalidixic acid sodium salt hydrate; Up 200; 14.6uM; PC3; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 7367_UP | |
| Drug | Cefoxitin sodium salt [33564-30-6]; Down 200; 8.8uM; PC3; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 7148_DN | |
| Drug | Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 4806_DN | |
| Drug | haloperidol; Up 200; 10uM; HL60; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 1185_UP | |
| Drug | 5-aza-2′-deoxycytidine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 3.02e-04 | 199 | 67 | 5 | 920_DN | |
| Drug | Clorsulon [60200-06-8]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 7025_DN | |
| Drug | Vincamine [1617-90-9]; Up 200; 11.2uM; HL60; HT_HG-U133A | 3.02e-04 | 199 | 67 | 5 | 2367_UP | |
| Drug | AC1N7H7A | 3.03e-04 | 9 | 67 | 2 | CID004302459 | |
| Drug | Hesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A | 3.09e-04 | 200 | 67 | 5 | 2648_UP | |
| Drug | Naringin hydrate [11032-30-7]; Up 200; 6.6uM; PC3; HT_HG-U133A | 3.09e-04 | 200 | 67 | 5 | 4605_UP | |
| Disease | epilepsy (implicated_via_orthology) | 1.63e-06 | 163 | 65 | 6 | DOID:1826 (implicated_via_orthology) | |
| Disease | pulse pressure measurement | CACNA1D DLC1 ZFHX4 DYNC2H1 LRP1 RNF213 AKAP13 EIF2AK4 PLXNB2 SMAD3 NIN SOS2 | 4.58e-05 | 1392 | 65 | 12 | EFO_0005763 |
| Disease | episodic ataxia type 6 (implicated_via_orthology) | 7.13e-05 | 6 | 65 | 2 | DOID:0050994 (implicated_via_orthology) | |
| Disease | Colorectal Carcinoma | 1.51e-04 | 702 | 65 | 8 | C0009402 | |
| Disease | Abnormality of the face | 1.70e-04 | 9 | 65 | 2 | C4025871 | |
| Disease | generalized epilepsy with febrile seizures plus 2 (implicated_via_orthology) | 2.13e-04 | 10 | 65 | 2 | DOID:0111294 (implicated_via_orthology) | |
| Disease | Dravet syndrome (implicated_via_orthology) | 2.13e-04 | 10 | 65 | 2 | DOID:0080422 (implicated_via_orthology) | |
| Disease | generalized epilepsy with febrile seizures plus (implicated_via_orthology) | 3.11e-04 | 12 | 65 | 2 | DOID:0060170 (implicated_via_orthology) | |
| Disease | Colorectal Neoplasms | 3.67e-04 | 277 | 65 | 5 | C0009404 | |
| Disease | Headache | 3.86e-04 | 64 | 65 | 3 | HP_0002315 | |
| Disease | cerebellum cortex volume change measurement | 4.27e-04 | 14 | 65 | 2 | EFO_0021497 | |
| Disease | type 2 diabetes mellitus (is_implicated_in) | 5.60e-04 | 171 | 65 | 4 | DOID:9352 (is_implicated_in) | |
| Disease | asthma, endometriosis | 5.91e-04 | 74 | 65 | 3 | EFO_0001065, MONDO_0004979 | |
| Disease | Noonan-Like Syndrome With Loose Anagen Hair | 7.98e-04 | 19 | 65 | 2 | C3501846 | |
| Disease | Costello syndrome (disorder) | 7.98e-04 | 19 | 65 | 2 | C0587248 | |
| Disease | Noonan syndrome-like disorder with loose anagen hair | 7.98e-04 | 19 | 65 | 2 | C1843181 | |
| Disease | Cardio-facio-cutaneous syndrome | 7.98e-04 | 19 | 65 | 2 | C1275081 | |
| Disease | intraocular pressure measurement | 8.94e-04 | 509 | 65 | 6 | EFO_0004695 | |
| Disease | migraine disorder, Headache | 9.16e-04 | 86 | 65 | 3 | HP_0002315, MONDO_0005277 | |
| Disease | LEOPARD Syndrome | 1.07e-03 | 22 | 65 | 2 | C0175704 | |
| Disease | Calcium channel blocker use measurement | 1.27e-03 | 213 | 65 | 4 | EFO_0009930 | |
| Disease | Noonan Syndrome | 1.28e-03 | 24 | 65 | 2 | C0028326 | |
| Disease | FEV/FEC ratio | 1.43e-03 | 1228 | 65 | 9 | EFO_0004713 | |
| Disease | migraine disorder, pulse pressure measurement | 1.50e-03 | 26 | 65 | 2 | EFO_0005763, MONDO_0005277 | |
| Disease | lumbar disc degeneration | 1.74e-03 | 28 | 65 | 2 | EFO_0004994 | |
| Disease | corneal topography | 1.81e-03 | 109 | 65 | 3 | EFO_0004345 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| VQQHNGIIFQFVAFI | 1321 | Q9P2K8 | |
| QFLATSAGNQQALNF | 101 | Q12802 | |
| FSGNLQQVQALFQDE | 66 | Q96NS5 | |
| QFVQFNGGFSQEQLN | 206 | Q3LIE5 | |
| EVQLNFYQFLGVQQD | 61 | Q96KC8 | |
| QTSQGLQAQLAQAFF | 841 | Q8IWY9 | |
| QQNINIFSQDLFGQT | 221 | Q9H560 | |
| FPNQFRFVGNAQNTL | 1066 | P98198 | |
| AFETVLQIFNNNFKQ | 696 | Q9H2T7 | |
| GLAFQNTVNFKFEEN | 241 | Q2M385 | |
| QFTINFNTGVINVIA | 2226 | Q14517 | |
| GVTSQQEQNNVFFVI | 16 | Q9Y585 | |
| YFQNNQITSIQEGVF | 111 | Q06828 | |
| FFSDIHFGNIQQIND | 2256 | Q07954 | |
| FFISNEGNQNLFVVQ | 161 | P09529 | |
| VQAFAALNSNNFVRF | 841 | O60318 | |
| QANSEFFQILSQNGA | 91 | P56645 | |
| TLQQFVDNFFQSVLA | 1631 | O15031 | |
| QQVFQFFSKVLAQVQ | 106 | Q86V87 | |
| SNVFSNFEQTQIQEF | 21 | Q02045 | |
| ENEALQQFFEAQGAN | 6 | Q96LU7 | |
| QLTQELGTAFFQQQQ | 46 | P30613 | |
| NNQAFSVGQQLVFSF | 126 | P46459 | |
| DAFFGFQLSQEIKQQ | 516 | Q96MN2 | |
| EQQVTFTINFDFNLQ | 886 | P17301 | |
| FTINFDFNLQNLQNQ | 891 | P17301 | |
| NNIFFEFFIQNDQCQ | 211 | A8MWY0 | |
| VGLFDYNSQQQLFQR | 376 | Q14671 | |
| NENINQVVFVGNFLR | 511 | Q9BZ23 | |
| QFFNSSVIDVFNQRN | 3946 | Q8NCM8 | |
| FTFQTAQGNDIFQAV | 231 | Q99704 | |
| SFQEFVQIFSQFGNE | 186 | Q9UBT7 | |
| FIAQVNNYELDFGQI | 391 | O00341 | |
| FNAQNNGSNFQLEEI | 171 | P02765 | |
| IFIAQVNNFELNFGQ | 411 | P43003 | |
| FAAVAQLFQTTQGQQ | 186 | O95104 | |
| FQKAQQEFAAGVFSN | 311 | O14828 | |
| NNNFQTFPQAVLLLF | 1386 | Q01668 | |
| EFNQADFNATVQFIQ | 4211 | Q8TE73 | |
| IQNVEVNAGQFATFQ | 191 | P28827 | |
| LQQNIDVFSQDVFGQ | 251 | Q6S8J7 | |
| VDQNRQQQFAFLFGV | 186 | Q9BXD5 | |
| QQQFAFLFGVDEQLL | 191 | Q9BXD5 | |
| ILQVFQDLNNFNGVL | 856 | Q07890 | |
| NGNVFQDAVFNQTVT | 181 | P43307 | |
| FGNTAEQTEQFLQQN | 1116 | Q8N4C6 | |
| QGAFDFAQIFSLTQQ | 221 | Q96FV2 | |
| EIGQFQSFAEKNIFQ | 86 | Q8TBE7 | |
| FDGNQFQKAQAISAF | 66 | P05015 | |
| AFNSIFQNENFQLQL | 1406 | Q8N3P4 | |
| IEILQVFQELNNFNG | 856 | Q07889 | |
| PFNQSTFNNVVEQNF | 781 | Q96QB1 | |
| QNNGAFNETLFRNQL | 721 | P02786 | |
| ALQILQQTFFEGDQQ | 3051 | Q63HN8 | |
| FETSQQQGFGQALVF | 311 | Q5T6F2 | |
| ELQQQAAFFQPQFLN | 1656 | Q86UP3 | |
| DNFQGVLQNVRFVFG | 206 | P07996 | |
| FQNFQSIQFINGIAH | 426 | Q9H5L6 | |
| NGLNFSQVLFALNQT | 216 | A6NFA1 | |
| QEFAALLAQSVNQGF | 346 | P84022 | |
| DQQAFSVGLNQAIAF | 481 | Q96RF0 | |
| RAGTFQAFEQFGQQL | 1391 | Q13813 | |
| ENAVFPSQVNVANNF | 1316 | O60281 | |
| LFTFQFNNLGNTDIN | 711 | Q9Y4E8 | |
| LNGLNFSQVIFALNQ | 216 | Q86V40 | |
| QGFIFDVVTSQAFNV | 1241 | Q01118 | |
| NLFIGVIIDNFNQQQ | 1301 | Q9UI33 | |
| SFGFEINLQENQNAL | 551 | P01266 | |
| FLQNVLNNQQFLAGT | 461 | P11498 | |
| LNNQQFLAGTVDTQF | 466 | P11498 | |
| NLQSQFNLENVTVFN | 176 | Q96FV9 |